Bullish
ResMed (RMD) Added to Goldman Sachs' APAC Conviction List
Goldman Sachs has included ResMed (RMD) in its APAC Conviction List, maintaining a Buy rating and setting a price target of A$46.70. This endorsement ...
RMD
--
--
--
--
Price Chart (30 Days)
Ad Space
Analyst Sentiment
Bullish (4)
Neutral (9)
Bearish (1)
Latest RMD News
Bullish
Neutral
Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
Resmed (NYSE: RMD, ASX: RMD) announced it will release its fourth quarter fiscal year 2026 financial and operational results on Thursday, August 6, 20...
Neutral
Resmed sets Aug. 6 webcast for fiscal Q4 results
Resmed (NYSE: RMD) announced it will release its fourth quarter fiscal year 2026 financial and operational results on Thursday, August 6, 2026, after ...
Neutral
Price to earnings forward of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – MUN:RMEA
This article provides financial information for ResMed Inc. CHESS Depositary Interests (RMEA) on the Munich Stock Exchange, specifically focusing on i...
Neutral
ResMed Shares Fall After Morgan Stanley Downgrade
ResMed (RMD) shares fell following a downgrade from Morgan Stanley, whose analysts cited increased competition from Eli Lilly's Zepbound for sleep apn...
Bullish
ResMed Inc. Stock 12‑Month Price Target Cut to $277.74, Implies 43% Upside
The average 12-month price target for ResMed Inc. (RMD) stock has been revised down slightly to $277.74 from $280.18, with individual analyst forecast...
Neutral
This ResMed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Several Wall Street analysts have downgraded key stocks including Ellington Financial Inc., Leidos Holdings, Inc., Ermenegildo Zegna N.V., Simulations...
Bearish
ResMed added as new short idea at Hedgeye
Hedgeye has added ResMed (RMD) as a new short idea, predicting a potential 30% decline in its share price. The rationale behind this forecast is the i...
Bullish
ResMed: GLP-1 Threats Are Overstated (NYSE:RMD)
The author believes that concerns about GLP-1 drugs impacting ResMed (RMD) are overblown, arguing that while some market share may be lost, the remain...
Neutral
ResMed chairman & CEO Michael Farrell sells $968k in stock
Michael J. Farrell, Chairman and CEO of ResMed Inc., sold 4,991 shares of the company's common stock for $968,064 on June 8, 2026, after exercising op...
Resmed Insider Sold Shares Worth $968,064, According to a Recent SEC Filing
An insider at ResMed (RMD) recently sold shares valued at $968,064, as disclosed in a filing with the U.S. Securities and Exchange Commission (SEC). T...
Neutral
ResMed (NYSE: RMD) CEO sells 4,991 shares after option exercise
ResMed's Chairman and CEO, Michael J. Farrell, exercised options to acquire 4,991 shares of company stock at $146.34 per share and subsequently sold t...
Neutral
ResMed Inc. $RMD Shares Sold by Marietta Investment Partners LLC
Marietta Investment Partners LLC significantly reduced its stake in ResMed Inc. ($RMD) by 87.7% in the fourth quarter, selling 8,648 shares. This sale...
Bullish
Resmed completes $340M Noctrix takeover
Resmed has completed its $340 million acquisition of Noctrix Health, adding a noninvasive device for restless legs syndrome (RLS) to its product portf...
Research RMD on:
Ad Space